Nanopublication: RAwK6HXBx9

Full identifier: http://purl.org/np/RAwK6HXBx9COTMrSUX5NwAK3oM6udTiMo3oUmQfBOTWDk

Raw formats: TriG(html,txt), JSON-LD(txt), N-Quads(txt), XML(txt)

Checking for updates...

 RAwK6HXBx9 comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAwK6HXBx9...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "methotrexate is indicated in the treatment of gestational choriocarcinoma chorioadenoma destruens and hydatidiform mole in acute lymphocytic leukemia methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents methotrexate is also indicated in the treatment of meningeal leukemia methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer epidermoid cancers of the head and neck advanced mycosis fungoides cutaneous t cell lymphoma and lung cancer particularly squamous cell and small cell types methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non hodgkin s lymphomas methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse free survival in patients with non metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor methotrexate is indicated in the symptomatic control of severe recalcitrant disabling psoriasis that is not adequately responsive to other forms of therapy but only when the diagnosis has been established as by a biopsy and or after dermatologic consultation methotrexate is indicated in the management of selected adults with severe active rheumatoid arthritis acr criteria or children with active polyarticular course juvenile rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first line therapy including full dose non steroidal anti inflammatory agents nsaids aspirin nsaids and or low dose steroids may be continued although the possibility of increased toxicity with concomitant use of nsaids including salicylates has not been fully explored see precautions drug interactions" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAwK6HXBx9... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-15T17:59:26.288+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAwK6HXBx9... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAwK6HXBx9... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAwK6HXBx9... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
show references